September 23, 2025 7:51am

I am still of the opinion, “my hang-up or same-old mantra, every time I see a new high; I am of the opinion to say BYE.” And grab “some” with profit capacity

Prepping for the end of September as Q3 is coming to a close – 6 sessions to go

News: Moderna (MRNA +$0.24 or +0.90% pre-open) <see below>

Pre-Open Signals: 5 Positive and 2 Negative

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

 

 

News: Moderna (MRNA) announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE® (COVID-19 Vaccine, mRNA) which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The data from an ongoing P4 clinical trial evaluating the safety, tolerability and immunogenicity of the 2025-2026 formula of mNEXSPIKE showed, on average, greater than a 16-fold increase in neutralizing antibodies against the LP.8.1 variant in individuals 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. These findings follow additional preliminary data that showed the 2025-2026 formula of Spikevax® generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across the same age groups.

 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

As I have written, "cell and gene therapy sector investors are existing in a catalyst vacuum”!

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in your portfolio for the short-term

 

Monday night’s … RMi Closing Bell: pop goes the sector … https://www.regmedinvestors.com/articles/14117

Updated … RMi Research Note: Harvard Apparatus GT (OTCQB): Who is wasting lipstick on this pig? … https://www.regmedinvestors.com/articles/13812

 

Tuesday: The pre-open Dow futures are UP +0.06% or (+30 points), the S&P futures are DOWN -0.06% or (-4 points) and the Nasdaq futures are DOWN -0.04% or (-9 points)

  • Stock futures are barely flipping mixed Tuesday, 9/23
  • Europe markets traded higher,
  • Asia Pacific markets were trading higher with Japan on holiday

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Monday: The Dow closed UP +66.27 points or +0.14%, the S&P closed UP +29.39 points or +0.44% while the Nasdaq closed UP +157.50 points or +0.70%
  • Friday: The Dow closed UP +172.856 points or +0.37%, the S&P closed UP +32.40 points or +0.49% while the Nasdaq closed UP +160.751 points or +0.72%
  • Last week: The Dow was up +1%, the S&P 500 +1.2% and the Nasdaq +2.2%.

Economic Data Docket: (9:45 am) S&P flash U.S. services PMI - Sept. and S&P flash U.S. manufacturing PMI, speeches: 1 Fed president (Bostic), 1 Vice-Chair (Bowman) and a lunch speech by Fed Chair Powell

 

Q3 – September, 1 holiday, 7 negative and 8 positive closes

  • August - 11 negative and 9 positive closes
  • July – 1 market holiday, 13 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • I see red after as September closes to the Q, along with the usual ups, downs and just plain uncertainties

Athough:

Alnylam Pharmaceuticals (ALNY) closed up +$5.36 after Friday’s +$1.39 after Thursday’s +$0.45 and Wednesday’s -$9.51 with a negative -$0.90 or -0.20% pre-open

Vertex Pharmaceuticals (VRTX) closed up +$0.01 after Friday’s -$3.99, Thursday’s -$0.04, Wednesday’s -$4.21 and last Tuesday’s -$1.85 with a negative -$0.13 or -0.03% pre-open

Intellia Therapeutics (NTLA) closed up +$1.67 after Friday’s -$0.52, Thursday’s +$3.70, Wednesday’s +$0.14 and last Tuesday’s +$0.70 following the previous Monday’s +$0.15 with a positive +$0.19 or +0.98% pre-open

CRISPR Therapeutics (CRSP) closed down -$0.22 after Friday’s -$0.62, Thursday’s +3.87, Wednesday’s -$2.12 and last Tuesday’s +$3.35 following the previous Monday’s +$1.58 with a positive +$0.04 or -0.06% pre-open

BioNTech SE (BNTX) closed up +$0.27 after Friday’s -$0.09, Thursday’s -$1.84, Wednesday’s -$1.11 and last Tuesday’s +$1.3 following the previous Monday’s +$1.14 with a positive -$0.05 or +0.05% pre-open

Moderna (MRNA) closed up +$1.32 after Friday’s +$0.45, Wednesday’s +$0.16, and last Tuesday’s +$0.96 following the previous Monday’s +$0.37 with a positive +$0.24 or +0.90% pre-open and with news

Sarepta Therapeutics (SRPT) closed up  +$1.22 after Friday’s -$1.09 with a positive +$0.53 or +2.84% pre-open

 

The BOTTOM LINE: “It’s always darkest before the pitch dark” …

A good, better/best Monday session after Friday’s huge decline with …

The market facing elevated risk into the end of the week, soon to be month of September and Q3 to early October.

While the market may be poised for even more upside through the end of 2025, there might be some near-term pressure in store.”  <Jonathan Krinsky, chief market technician at BTIG>

 

September is in the front window: understand the “flow”

  • 9/22 - Monday closed positive with 31 positive, 9 negative and 0 flat

Last week:

  • 9/19 – Friday closed negative with 7 positive, 33 negative and 0 flat
  • 9/18 – Thursday closed positive with 33 positive, 6 negative and 1 flat
  • 9/17 – Wednesday closed negative with 10 positive, 30 negative and 0 flat
  • 9/16 – Tuesday closed positive with 29 positive, 9 negative and 2 flats
  • 9/15 – Monday closed negative with 17 positive, 22 negative and 1 flat

 

September has historically delivered pullbacks, yet, this year’s 2025 market has defied that pattern — climbing 35% since March with strong technical and fundamental tailwinds,

Q2 Earnings are in the rear-view mirror; we are about to start again … Q3!

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.